Leerink Partners analyst Danielle Antalffy maintained a Hold rating on Becton Dickinson (BDX – Research Report) on January 24 and set a price target of $270.00. The company’s shares closed last Thursday at $271.94.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Becton Dickinson with a $286.86 average price target, implying a 4.1% upside from current levels. In a report issued on February 3, UBS also maintained a Hold rating on the stock with a $280.00 price target.
The company has a one-year high of $280.62 and a one-year low of $235.13. Currently, Becton Dickinson has an average volume of 1.42M.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1897, Becton, Dickinson & Co. is a New Jersey-based medical technology company. The company develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional.
Read More on BDX: